About us - Newsroom - Media releases

Media releases

View 10 | 50 | 100 entries/page
Showing 1 - 6 of 6

Cell separation – faster and more reliable than ever

New: The MultiMACS™ X raises fully automated, walk-away, high-throughput cell separation to a new level


November 2, 2017

New: MACSQuant® X revolutionizes high-throughput flow cytometry

Miltenyi Biotec is launching a new era in the field of fully automated high-throughput flow cytometry analysis: Now up to 384-well plates can be handled in less than 60 minutes giving users fast, reliable, and reproducible results. This is made possible by the MACSQuant® X – a benchtop instrument that gives you all the flexibility and is easy to use.


September 14, 2017

Natural Killer Cells: Cultivation, Activation and Growth

Miltenyi Biotec extends its product portfolio in the area of cell culture media with the NK MACS® Medium


August 4, 2017

Miltenyi Biotec named as an employer for the future

In its current issue, the news magazine “Focus” has published the results of a survey with the title “Germany’s best jobs with a future“.


July 3, 2017

New: MACS® GMP T Cell TransAct™ from Miltenyi Biotec

MACS® GMP T Cell TransAct™ is a ready-to-use reagent for efficient in vitro activation and expansion of human T cells. Also available in research grade.


April 20, 2017

The EU-funded project CARAT offers fellowships for a training course on CAR T cell manufacturing

The EU project CARAT has taken on the mission to deliver new tools and technologies to enable the wide use of novel personalized cancer treatment options. In 2017, CARAT will grant five scientists with a fellowship that gives them the opportunity to participate in a unique training.


January 24, 2017

View 10 | 50 | 100 entries/page
Showing 1 - 6 of 6

Customer login

Go

Forgot password?
Register for account

0 Shopping cart

Contact

Miltenyi Biotec Inc.
Phone: +1 800 FOR MACS
Fax:+1 877 591 1060
macs@miltenyibiotec.com
Contact overview

Product finder

Antibody panel builder

Toolbox

Loading...
Media contact

Media contact

Your opinion matters

Your opinion matters

Change country

Please select your country to continue